Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.
What Poses the Greatest Risk to Markets?
by John Blank
The Nov. election, coronavirus, or earnings results?
Deciphera's NDA for GIST Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.
The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer
Coronavirus Update: Global Week Ahead
by John Blank
In the Global Week Ahead, the global economy and China will be reeling from the spread of a novel pneumonia or flu-like coronavirus.
Blueprint Medicines' NDA for Avapritinib Gets Extended Review
by Zacks Equity Research
FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
by Zacks Equity Research
Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.
The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty
by Benjamin Rains
Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn
by Zacks Equity Research
Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & Gamble Company (PG) and Pfizer Inc. (PFE).
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Bayer Seeks FDA Approval for New Formulation of Nifurtimox
by Zacks Equity Research
Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.
Apple, Starbucks & eBay Earnings Previews & A Strong Buy Retail Stock - Free Lunch
by Benjamin Rains
What investors can expect from Apple, Starbucks, and eBay earnings Tuesday. The episode then ends with why Guess?, Inc. (GES) is a Zacks Rank #1 (Strong Buy) stock right now...
Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
by Zacks Equity Research
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.